Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy (Q36142278)

12 August 2017

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy (English)

1 reference

12 August 2017

0 references

1 reference

Hans Lilja

11

0 references

Andrew Vickers

object named as

Andrew J Vickers

1

0 references

Jonas Hugosson

9

object named as

Jonas Hugosson

1 reference

12 August 2017

6

Monique J Roobol

1 reference

12 August 2017

10

Fritz H Schröder

1 reference

12 August 2017

Tineke Wolters

2

1 reference

12 August 2017

Caroline J Savage

3

1 reference

12 August 2017

Angel M Cronin

4

1 reference

12 August 2017

M Frank O'Brien

5

1 reference

12 August 2017

Gunnar Aus

7

1 reference

12 August 2017

Peter T Scardino

8

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

12 August 2017

1 reference

12 August 2017

184

1 reference

12 August 2017

3

1 reference

12 August 2017

907-912

1 reference

Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

A novel nomogram to predict the probability of prostate cancer on repeat biopsy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3412428

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

5 December 2018

1 reference

12 December 2020

Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy

1 reference

12 December 2020

Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men

1 reference

12 December 2020

[Importance of PSA velocity and PSA density in the prediction of prostate cancer in TURP or open prostatectomy specimen of patients with previous negative prostate biopsy]

1 reference

12 December 2020

10.1016/J.JURO.2010.05.029

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

20643434

1 reference